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Background: Uninterrupted transmission of highly pathogenic avian influenza virus (HPAIV) H5N1 of clade 2.2.1 in
Egypt since 2006 resulted in establishment of two main genetic clusters. The 2.2.1/C group where all recent human
and majority of backyard origin viruses clustered together, meanwhile the majority of viruses derived from
vaccinated poultry in commercial farms grouped in 2.2.1.1 clade.
Findings: In the present investigation, an HPAIV H5N1 was isolated from twenty weeks old layers chickens that
were vaccinated with a homologous H5N1 vaccine at 1, 7 and 16 weeks old. At twenty weeks of age, birds showed
cyanosis of comb and wattle, decrease in egg production and up to 27% mortality. Examined serum samples
showed low antibody titer in HI test (Log2 3.2± 4.2). The hemagglutinin (HA) and neuraminidase (NA) genes of the
isolated virus were closely related to viruses in 2.2.1/C group isolated from poultry in live bird market (LBM) and
backyards or from infected people. Conspicuous mutations in the HA and NA genes including a deletion within the
receptor binding domain in the HA globular head region were observed.
Conclusions: Despite repeated vaccination of layer chickens using a homologous H5N1 vaccine, infection with
HPAIV H5N1 resulted in significant morbidity and mortality. In endemic countries like Egypt, rigorous control
measures including enforcement of biosecurity, culling of infected birds and constant update of vaccine virus
strains are highly required to prevent circulation of HPAIV H5N1 between backyard birds, commercial poultry, LBM
and humans.
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Background
A devastating highly pathogenic avian influenza virus
(HPAIV) of H5N1 subtype first emerged in poultry and
further transmitted to human in Hong Kong in 1997 [1].
The spread of the H5N1 virus to Europe and Africa was
due to a large-scale outbreak of H5N1 infection that oc-
curred in migratory waterfowl in Qinghai Lake (China)
in 2005 [2]. To date, ten different genetic clades (0 – 9)
of H5N1 virus have been distinguished which further di-
versified into subclades [3]. The HPAIV H5N1 of clade
2.2.1 has been introduced into Egypt in early 2006 [4]
probably via infected wild ducks [5]. Despite control
efforts, the virus had become endemic in poultry in* Correspondence: monaaly5@hotmail.com; hafez@vetmed.fu-berlin.de
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distribution, and reproduction in any mediumEgypt since 2008 [6]. Egypt embarked mainly on inacti-
vated H5N1 and H5N2 vaccines to limit the spread of
H5N1 virus and minimize its socioeconomic impacts
[7]. However, circulation of the HPAIV H5N1 in different
poultry species (chickens, ducks, turkeys, etc.), in addition
to donkeys and possibly pigs was reported [8-10]. More-
over, out of 168 infected human in Egypt, 60 cases were
fatal until July 27, 2012 [11].
In Egypt, H5N1 isolated from humans and a large
group of viruses isolated from backyard ducks and
chickens clustered in a distinct genetic group designated
“2.2.1/C” [12], meanwhile, majority of viruses derived
from vaccinated poultry in commercial farms were
found in newly named 2.2.1.1 clade [3,13]. A virus
belonging to 2.2.1/C group has been also isolated from
donkeys in Egypt [8]. Those 2.2.1/C viruses harbor con-
spicuous mutations in the HA and NA proteins, were
thought to be responsible for decreasing virulence intral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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population [14,15]. On the contrary, viruses cluster in
clade 2.2.1.1, also known as variant 2.2.1 viruses, had ex-
tensive amino acids substitutions in or adjacent to the
immunogenic epitopes at the proximal globular head re-
gion of the HA protein which could enable continuous
circulation of the virus in and among commercial
poultry despite large scale vaccination campaigns
[16,17]. Regular nationwide active, passive and targeted
surveillance revealed that HPAV H5N1 is perpetuated in
many commercial farms, backyards and live bird mar-
kets (LBM) [4,7,9,16,18]. Culling of infected birds occurs
infrequently in Egypt [6].
Backyard birds and commercial poultry are kept in
very close contact with humans due to integration of
both farms and houses in the same buildings. Employees
in commercial farms usually maintain their own house-
hold birds. Furthermore, selling of remaining feed, uten-
sils and equipment from commercial farms to the rural
family poultry often occurs in Egypt. Backyard chickens,
ducks and geese are mostly reared together and roam
freely in the vicinity of the house in close contact with
human, particularly children. More than 70% of the
Egyptian poultry production from commercial or back-
yard sectors is marketed through LBM [6]. All H5N1
infected human cases, except three cases, were linked to
direct contact of human with sick or apparently healthy
birds in backyards and/or LBM [19].
Here we describe the isolation and molecular
characterization of an HPAI H5N1 virus isolated from
twenty weeks old chicken layer flock, which was vacci-
nated three times with a commercial inactivated H5N1
vaccine.
Methodology
A commercial chicken farm with 23,699 Hisex-brown
layers kept in cages; chickens were vaccinated three
times at weeks 1, 7, and 16 with a commercial inacti-
vated H5N1 vaccine seeded by A/Goose/Guangdong/1/
1996/H5N1 (Re-1 YEBIO, Harbin, China). Vaccination
of birds was conducted by the owner as part of usual
practice. Ten tracheal swabs and ten cloacal swabs were
collected randomly at day 7 after onset of clinical signs.
At the same time, ten serum samples were collected for
further laboratory investigation. Ten swabs were pooled
according to Manual of Diagnostic Tests and Vaccines
for Terrestrial Animals [20]. No experimental research
was conducted in this study and the birds were handled
according to the standard guidelines [20]. Samples were
collected during the routine nationwide influenza sur-
veillance program after the ministerial decree number
221/2006 in charge the National Laboratory for Veterin-
ary Quality Control on Poultry Production (NLQP) for
official diagnosis and surveillance of AIV in Egypt.Virus isolation trials were carried out in 10-day-old
SPF hatching eggs via allantoic sac inoculation [20]. The
virus titer was estimated by mean egg-infective dose
(EID50/0.1mL) according to Reed and Muench [21]. For
detection of avian influenza H5–specific antibodies in
the serum samples; hemagglutination inhibition (HI) test
was performed in V-bottom; 96-well microtiter plates
with four hemagglutinating units (4HAU) of the indi-
cated homologous A/Goose/Guangdong/1/1996 H5N1
antigen, supplied by the vaccine-producing company
(YEBIO, Harbin, China) and 1% of chicken erythrocytes
according to the standard protocol [20]. Results were
interpreted as the reciprocal of the last well that showed
complete inhibition of the hemagglutination activity of
the used H5 antigen.
Viral RNA from fluid of pooled swabs was extracted
using a MagNA Pure LC Total Nucleic Acid Extraction
kit following manufacturer’s instructions and MagNA
Pure LC instrument (Roche, Mannheim, Germany). The
RT-qPCR reaction was done using one step Real-Time
PCR Kit (Qiagen, Valencia, CA.) as recommended by the
manufacturer. Partial matrix (M) gene segment of AIV
from viral RNA was amplified according to Spackman
et al. [22] using forward primer 50-AGA TGA GTC TTC
TAA CCG AGG TCG-30, reverse primer 50-TGC AAA
AAC ATC TTC AAG TCT CTG-30and probe 50 FAM-
TCA GGC CCC CTC AAA GCC GA-TAMRA-30. The
RT-qPCR reaction was done in Stratagene MX3005P real
time PCR machine (Stratagene, Agilent Technologies,
Santa Clara, CA). Thereafter, H5 and N1 genes were
amplified using generic avian influenza virus H5N1 Real
Time RT-PCR RT3 Kits (Roche, Mannheim, Germany)
according to the manufacturer guidelines in LightCyclerW
2.0 machine.
Amplification of the open reading frame of the HA and
NA gene segments was conducted as previously
described [16]. The full coding sequences of the HA and
NA genes of the isolated virus were conducted using Big-
Dye Terminator v3.1 Cycle Sequencing Kit on an auto-
matic sequencer (ABI-3130; Applied Biosystems, Foster
City, CA). The produced sequences were aligned with
BioEdit version 7.0.9.0 [23]. Amino acid sequence was
deduced and a BLASTN search was performed to identify
the query sequence and to find similar sequences. Phylo-
genetic trees of the obtained H5 and N1 genes and other
relevant H5N1 genes retrieved from the GenBank data
base were generated using the neighbor-joining method
with 1000 bootstrap replicates and the evolutionary dis-
tances were computed using the Maximum Composite
Likelihood method implemented in MEGA5 [24]. Trees
were edited for publication using Inkscape software 0.48.1
as shown in Figure 1. Prediction of N-linked glycosylation
sites was done by the NetNGlyc 1.0 Server that examines
the sequence context of N–X–S/T sequons [25].
Figure 1 Phylogenetic trees of H5 (A) and N1 (B) genes of A/chicken /Egypt/0987-NLQP/2009 virus with other H5N1 viruses currently
circulating in poultry and human in Egypt. The evolutionary history of the HA and NA was inferred using the Neighbor-Joining method with
1000 bootstrap replicates and the evolutionary distances were computed using the Maximum Composite Likelihood method implemented in
MEGA5. The bootstrap values are shown next to the branches. Trees were edited for publication using Inkscape software. Virus obtained from this
study is highlighted in yellow while other related viruses are written in bold. The virus clustered with H5N1 viruses isolated from poultry in
backyards, live bird market and confirmed human infections. Two major H5N1 genetic clusters are currently co-circulating in Egypt: newly
designated 2.2.1.1 clade (depicted in red) representing variant viruses isolated exclusively from vaccinated poultry in commercial farms and group
C of 2.2.1 clade (blue) denoted 2.2.1/C group that mainly isolated from human and backyard birds according to the recent classification of WHO/
OIE/FAO Evolution Working Group. The 2.2.1 index virus introduced into 2006 (black) was no longer isolated and was denoted as 2.2.1 clade.
El-Zoghby et al. Virology Journal 2012, 9:294 Page 3 of 8
http://www.virologyj.com/content/9/1/294The virus isolated in this study was designated as A/
chicken/Egypt/0987-NLQP/2009(H5N1) and referred to
as “Layer/0987”. Identity matrix of the isolated virus
with other six H5N1 viruses was done: (1) A/goose/
Egypt/09324sm-NLQP/2009 [GenBank: GU811737 and
HM352793 for the HA and NA genes, respectively]
isolated from geese in live bird market (LBM) in the
same region and referred to as LBM/Gs. (2) A/duck/
Egypt/0918-NLQP/2009 [GenBank: GU002674 and
HQ908452] isolated from backyard birds referred to as
BY/Dk. (3) A/Egypt/N02039/2009 [GenBank: CY041918
and CY041919] was detected from 32 months old boy
few days before the incidence of the current outbreak
in commercial-layer flock from the same village (case
number 57 in the WHO [26]) and referred to as
Human/N02039. Those three viruses belong to the2.2.1/C group. (4) A/chicken/Egypt/06207-NLQP/2006
[GenBank: EU372943 and GQ184251] was isolated in
February 2006 and referred to as Index/2006. (5) A/
chicken/Egypt/1055/2010 [GenBank: HQ198268 and
HQ908478] a representative virus of the 2.2.1.1 variant
clade that was isolated from vaccinated chickens and
referred to as Variant/1055. (6) Layer chickens in this
study were vaccinated by a commercial vaccine modi-
fied by reverse genetic where monobasic-HA and NA
genes originated from H5N1 A/Goose/Guangdong/1/96
[GenBank: AF144305 and AF144304] referred to as
GsGd/96. The latter was considered to be the parent
virus of clade 2.2 [27]. Numbering of amino acid resi-
dues of the HA (H5 numbering after removal of the
signal peptide) and NA proteins were done in compari-
son to GsGd/96 as standard (N1 numbering).
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mers were generated as PDB using 3D-JIGSAW from
Index/2006 virus [28]. Location of amino acid substitu-
tions was imposed on the HA and NA proteins using
RasTop software version 2.7.1 [29] and further edited by
Inkscape.
Results
At twenty weeks of age, some birds showed cyanosis of
comb and wattles, hemorrhages on the shank and a total
mortality estimated to be 27%. In addition, there was a
drop in egg production (20%) and an increase of the
number of misshaped eggs (depigmentation, soft egg-
shell, shell-less and rough eggs). The course of the dis-
ease took more than 21 days from onset of clinical
illness until depopulation of the flock.
After inoculation of embryonated chicken eggs with
tracheal and cloacal swabs media, all embryos died
within 48 hours post inoculation. Hemagglutination ac-
tivity in the harvested allantoin fluid was determined.
The isolated virus was confirmed to be an H5N1 virus
by partial amplifications of the M, HA and NA genes of
avian influenza viruses using specific real-time reverse
transcription– polymerase chain reaction (RT-qPCR).
The median egg infectious dose was 7.2 EID50/0.1mL.Table 1 Percentage identity of the hemagglutinin and neuram
in relation to other Egyptian H5N1 viruses and vaccine strain
Hemagglutinin 1Layer/0987 2LBM/Gs 3BY/Dk 4Hu
Layer/0987 99.77 99.83 99.7
LBM/Gs 99.65 99.94 99.8
BY/Dk 99.65 100.00 99.9
Human/N02039 99.47 99.82 99.82
Index/2006 98.94 99.29 99.29 99.1
Variant/1055 94.89 95.24 95.24 95.0
GsGd/96 94.53 93.47 94.71 94.5
Neuraminidase Layer/0987 LBM/Gs BY/Dk Hu
Layer/0987 99.85 99.64 99.5
LBM/Gs 99.78 99.75 99.7
BY/Dk 99.49 99.58 99.4
Human/N02039 99.55 99.70 99.41
Index/2006 98.88 99.10 98.98 98.8
Variant/1055 97.96 98.19 97.96 97.9
GsGd/96 92.04 92.26 91.35 92.0
Percentage identity of nucleotide (above the diagonal) and amino acid (below the
1 The virus isolated in this study was designated as A/chicken/Egypt/0987-NLQP/20
and NA genes, respectively.
2 A/goose/Egypt/09324sm-NLQP/2009 [GenBank: GU811737 and HM352793] isolate
3 A/duck/Egypt/0918-NLQP/2009 [GenBank: GU002674 and HQ908452] isolated from
4 A/Egypt/N02039/2009 [GenBank: CY041918 and CY041919] isolated from 32 mont
5 A/chicken/Egypt/06207-NLQP/2006 [GenBank: EU372943 and GQ184251] was isola
6A/chicken/Egypt/1055/2010 [GenBank: HQ198268 and HQ908478] variant 2.2.1.1 vi
7 A/Goose/Guangdong/1/96 [GenBank: AF144305 and AF144304] vaccine strain useSerum samples collected at 7 days after the onset of clin-
ical signs had mean HI titer of 3.2 log2 (standard devi-
ation ± 4.3 log2) using homologous A/Goose/
Guangdong/1/1996 H5N1 antigen, supplied by the
vaccine-producing company (YEBIO, Harbin, China).
The full coding H5 and N1 gene sequences generated
in this study were submitted to GenBank under acces-
sion numbers GU366078 and HQ908461 for the HA
and NA genes, respectively. A/chicken/Egypt/0987-
NLQP/2009(H5N1) isolated in this study had 99.76%
and 99.65% HA and 99.85% and 99.78% NA nucleotides
and amino acids identity, respectively with an H5N1
virus isolated from LBM from the same village as shown
in Table 1. A/chicken/Egypt/0987-NLQP/2009 had
99.82% and 99.65% HA and 99.64% and 99.49% NA
nucleotides and amino acids identity, respectively with
an H5N1 virus isolated from backyard birds in addition
to 99.77% and 99.47% HA and 99.55% and 99.55% NA
nucleotides and amino acids identity, respectively with
an H5N1 virus isolated from 32 months old boy from
the same village. However, the virus isolated in this
study had nucleotides and amino acids identities of
94.28% and 94.53% for the HA and 93.1% and 92.04%
for the NA with the vaccine strain (GsGd/96), respect-
ively as shown in (Table 1). Both HA and NA genesinidase sequences of A/chicken/Egypt/0987-NLQP/2009
man/N02039 5 Index/2006 6Variant/1055 7GsGd/96
7 98.90 96.19 94.28
8 98.96 96.19 94.46





man/N02039 Index/2006 Variant/1055 GsGd/96
5 98.58 97.30 93.01
8 98.73 97.43 91.54






09 under GenBank accession numbers GU366078 and HQ908461 for the HA
d from geese in live bird market (LBM) in the same region.
backyard birds.
hs old boy from the same village.
ted in February 2006 and represents the index 2.2.1 Egyptian viruses.
rus isolated from vaccinated chickens in a commercial farm.
d in vaccination of the current commercial layer flock.
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lated from vaccinated commercial poultry in 2.2.1.1
clade (Figure 1).
The proteolytic cleavage site of the HA had polybasic
amino acid motif “ERRRKKR/GLF”, typical for HPAIV
of clade 2.2. A deletion within the receptor binding site
at position 129S (H5 numbering) and additional four
amino acid substitutions namely; D43N, S120N, I151T
and S320G of viral H5 protein in comparison to H5N1
virus introduced into Egypt in 2006 (Index/2006) were
found. All mutations located in the HA1 on the globular
head domain (Figure 2). In addition, 14 synonymous
mutations were also found. Seven potential glycosylation
sites (residues 11, 23, 165, 193, 286, 484 and 543) in the
HA protein were predicted. De-glycosylation (loss of as-
paragine and existence of aspartic acid instead) of amino
acid residue 154 was observed.
The NA of A/chicken/Egypt/0987-NLQP/2009 has a
deletion of 20 amino acids in the stalk region (49 – 68;
N1 numbering) in comparison to GsGd/96. Further-
more, in comparison to H5N1 virus introduced into
Egypt in 2006, A/chicken/Egypt/0987-NLQP/2009 had
five amino acid substitutions in the NA protein namely;
A46D, N200D, L224M, S339V, and S450G and 14 syn-
onymous mutations in the NA gene. There was no mo-
lecular marker of neuraminidase inhibitor resistance.






Figure 2 Predicted location of amino acid substitutions found in the
(B) monomers. Shown are the substitutions in D43N, S120N, I151T and S3
proteins. Substitutions have been imposed upon the tertiary structure of A
introduced into Egypt in early 2006). Protein modeling was generated by J
Inkscape.glycosylation sites; residues 68, 126 and 215. On the
contrary, GsGd/96 virus had additional four potential
glycosylation sites that located in the deleted stalk region
of A/chicken/Egypt/0987-NLQP/2009.
Discussion
Twenty weeks old layer chickens flock vaccinated three
times with inactivated H5N1 vaccine suffered from re-
spiratory distress and some birds had signs commonly
seen in poultry infected with HPAIV. HPAIV H5N1 was
isolated from tracheal and cloacal swabs media collected
after onset of clinical signs during regular national sur-
veillance. Full H5 and N1 coding gene sequences showed
a close genetic relationship between the obtained virus
and viruses of LBM, backyards and human origins. Due
to insufficiency of epidemiological data, the source of
this infection through either LBM, backyard birds or
from humans cannot be deduced.
Despite repeated vaccination using a homologous
H5N1 vaccine, the chickens exhibited observable distress
and mortality. This suggests updated poultry vaccine
may be necessary in endemic areas like Egypt. Tian et al.,
[30] found that the HI titer of > 4log2 indicated sufficient
protection of vaccinated chickens against HPAIV H5N1
infection. In this study, anti-H5 antibody titer was low
with variable individual titers (3.2 ± 4.3 log2) after three





isolated virus on the tertiary structure of HA H5 (A) and N1 NA
20G in the HA and A46D, N200D, L224M, S339V and S450G in the NA
/chicken/Egypt/06207-NLQP/2006(H5N1) (index virus of clade 2.2.1
IGSAW [28] and edited by RasTop version 2.7.1 and further edited by
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(SPF) chickens vaccinated with this inactivated H5N1 vac-
cine evoked high HI titer (7.0 ± 0.8 log2) and were pro-
tected against challenge with an Egyptian H5N1 virus
belonged to the 2.2.1/C group [31]. Therefore, we as-
sume that improper administration, mishandling and in-
appropriate storage of the vaccine [7] or suppression of
the immune system (i.e.: due to chicken anemia virus in-
fection or ingestion of mycotoxins) [32] could be respon-
sible for such weak immune response and subsequently
lack of protection. Moreover, the ability of inactivated
H5N1 vaccine to evoke effective immune response in Hi-
Sex brown layers remains to be investigated. Taken to-
gether, vaccination with regularly updated H5N1 vaccines
to protect poultry against the evolving H5N1 virus in
Egypt is highly recommended.
The high level of genetic identity of A/chicken/Egypt/
0987-NLQP/2009 to viruses in LBM markets and back-
yard birds suggests a direct transmission link which is
not uncommon scenario in Egypt. On the other hand,
close genetic relationship between A/chicken/Egypt/
0987-NLQP/2009 and H5N1 virus isolated from 32
months old boy from the same village could be explained
by existence of a common source of infection; most prob-
ably backyard birds and/or LBM [7,9]. However, another
possible source of infection could be human-to-chicken
transmission which instantly could neither be excluded
nor confirmed. Subclinical infections of human with
H5N1 virus probably due to poultry-to-human, limited
human-to-human transmission or environmental source
(s) have been reported in China, Cambodia, Vietnam,
Thailand and Turkey [33-37]. It is worth pointing out
that subclinical infections of apparently healthy pigs and
donkeys with HPAIV H5N1 have been reported in Egypt
[8,10]. Unfortunately there is a paucity of information on
subclinical spread among people in Egypt, particularly
those in close contact to infected backyard birds or
shared in culling of infected commercial farms. However,
since late 2008, symptomless cases infected with mild
virulent H5N1 in Egypt have raised concern that the virus
might be adapted to Egyptians without getting sick [38].
It is well known that affinity of H5N1 virus to avian-
type α2-3 and mammalian-like α2-6 linked sialic acid
receptors seems to be governed by a number of residues
in the HA protein including serine at position 129 which
is a part of the receptor binding domain (RBD) [39]. It
has been found that the Egyptian H5N1 viruses had a
potential to use mammalian receptors resembling sea-
sonal H1N1 virus [40]. Deletion of RBD 129S found in
A/chicken/Egypt/0987-NLQP/2009 (Figure 2) existed
also in all recent isolates of human and backyard origins
in Egypt but had neither been reported from the parent
GsGd/96 virus [27] nor from Index/2006, the virus ori-
ginally introduced into Egypt in 2006 . Intriguingly, virusisolated from donkeys belonged to the same 2.2.1/C sub-
lineage (Figure 1). Recently, deletion of RBD 129S com-
bined with I151T in this unique Egyptian genetic group
increased affinity of the Egyptian viruses to mammalian
receptors and retained its avian receptor specificity [15].
Mutation in this residue was associated with a less viru-
lent H5N1 phenotype causing milder or asymptomatic
courses of infection and increased transmissibility in
mice [41]. Interestingly, other significant substitutions
such as Q192R, G222L and Q224S associated with ad-
justment of the virus from avian to mammalian recep-
tors [42] were not observed in any Egyptian H5 gene
sequences, including A/chicken/Egypt/0987-NLQP/2009
[13].
It is well known that N-linked glycosylation of the HA
of influenza A viruses can affect receptor binding prefer-
ences or mask antigenic regions [41]. A/chicken/Egypt/
0987-NLQP/2009 like other recent Egyptian H5N1
viruses of human and backyard origin, lost the potential
glycosylation site at residue 154 (near the RBD) [13].
This phenotype was associated with (1) increase the af-
finity of H5 viruses to α2-6 residues [43], (2) increased
transmissibility in guinea pigs and decreased fatality and
systemic spread in mice [44]. Taken together, these clues
could support the possible scenario of human-to-poultry
transmission in Egypt. Therefore, infected human (farm
workers, dealers, visitors, etc.) in Egypt should be con-
sidered a possible source of infection not only mechan-
ical but also as a biological vector. Moreover, targeted
surveillance to identify subclinical infection of human in
Egypt should be taken in consideration to avoid a sud-
den emergence of pandemic virus. On the other hand,
residue A46 is located in the NA stalk region while the
others are positioned at the surface of the NA monomer
(Figure 2). None of NA mutations has a known bio-
logical function except 319S which is a part of an im-
munogenic epitope (C) (56). A similar deletion in
human H1N1 virus brought with it compensatory
changes in the NA to facilitate viral entry and release
and a similar mechanism may be acting on the 2.2.1/C
viruses of human origin in Egypt [45]. Recently, isolation
of H9N2 has been isolated from poultry in Egypt and
possible reassortment is expected [46-48].
In conclusion, circulation of HPAIV H5N1 in vaccinated
birds continues to devastate the poultry industry in Egypt.
Birds in backyards and LBM remain the main potential
source of H5N1 infection to both commercial poultry and
humans in Egypt. Targeted surveillance to elucidate the
spread of HPAIV H5N1 among commercial poultry work-
ers and/or householders should be considered.
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